TABLE OF CONTENTS
Volume 22, Issue 9 (September 2008)
Spotlight Review
Pathogenesis and progression of monoclonal gammopathy of undetermined significance FREE
J Bladé, L Rosiñol, M T Cibeira and C F de Larrea
Leukemia 22: 1651-1657; advance online publication, July 31, 2008; doi:10.1038/leu.2008.203
Review
Immunotherapy for myeloid leukemias: current status and future directions
K el-Shami and B D Smith
Leukemia 22: 1658-1664; advance online publication, June 19, 2008; doi:10.1038/leu.2008.148
Original Articles
Therapy
Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study
I M Appel, K M Kazemier, J Boos, C Lanvers, J Huijmans, A J P Veerman, E van Wering, M L den Boer and R Pieters
Leukemia 22: 1665-1679; advance online publication, June 26, 2008; doi:10.1038/leu.2008.165
A pilot pharmacokinetic study of oral azacitidine
G Garcia-Manero, M L Stoltz, M R Ward, H Kantarjian and S Sharma
Leukemia 22: 1680-1684; advance online publication, June 12, 2008; doi:10.1038/leu.2008.145
Acute Leukemias
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia
M T Voso, S Hohaus, F Guidi, E Fabiani, F D'Alò, S Groner, D Späth, K Doehner, G Leone, H Doehner and R F Schlenk
Leukemia 22: 1685-1691; advance online publication, June 26, 2008; doi:10.1038/leu.2008.169
Prenatal origin of childhood acute lymphoblastic leukemia, association with birth weight and hyperdiploidy
B Gruhn, J W Taub, Y Ge, J F Beck, R Zell, R Häfer, F H Hermann, K-M Debatin and D Steinbach
Leukemia 22: 1692-1697; advance online publication, June 12, 2008; doi:10.1038/leu.2008.152
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
S Park, N Chapuis, V Bardet, J Tamburini, N Gallay, L Willems, Z A Knight, K M Shokat, N Azar, F Viguié, N Ifrah, F Dreyfus, P Mayeux, C Lacombe and D Bouscary
Leukemia 22: 1698-1706; advance online publication, June 12, 2008; doi:10.1038/leu.2008.144
Chronic Myeloproliferative disorders
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
E J Feldman, J Cortes, D J DeAngelo, T Holyoake, B Simonsson, S G O'Brien, J Reiffers, A R Turner, G J Roboz, J H Lipton, F Maloisel, P Colombat, G Martinelli, J L Nielsen, S Petersdorf, F Guilhot, J Barker, P Kirschmeier, E Frank, P Statkevich, Y Zhu, S Loechner and A List
Leukemia 22: 1707-1711; advance online publication, June 12, 2008; doi:10.1038/leu.2008.156
Chronic Lymphocytic Leukemia
BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells
P Pérez-Galán, G Roué, M López-Guerra, M Nguyen, N Villamor, E Montserrat, G C Shore, E Campo and D Colomer
Leukemia 22: 1712-1720; advance online publication, July 3, 2008; doi:10.1038/leu.2008.175
Immunology
Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy
A S M Yong, K Keyvanfar, R Eniafe, B N Savani, K Rezvani, E M Sloand, J M Goldman and A J Barrett
Leukemia 22: 1721-1727; advance online publication, June 12, 2008; doi:10.1038/leu.2008.161
Apoptosis
The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
K Kojima, M Shimanuki, M Shikami, I J Samudio, V Ruvolo, P Corn, N Hanaoka, M Konopleva, M Andreeff and H Nakakuma
Leukemia 22: 1728-1736; advance online publication, June 12, 2008; doi:10.1038/leu.2008.158
Spongistatin 1: a new chemosensitizing marine compound that degrades XIAP
L Schyschka, A Rudy, I Jeremias, N Barth, G R Pettit and A M Vollmar
Leukemia 22: 1737-1745; advance online publication, June 12, 2008; doi:10.1038/leu.2008.146
Lymphoma
Pathway activation patterns in diffuse large B-cell lymphomas
S Bentink, S Wessendorf, C Schwaenen, M Rosolowski, W Klapper, A Rosenwald, G Ott, A H Banham, H Berger, A C Feller, M-L Hansmann, D Hasenclever, M Hummel, D Lenze, P Möller, B Stuerzenhofecker, M Loeffler, L Truemper, H Stein, R Siebert and R Spang
Leukemia 22: 1746-1754; advance online publication, June 26, 2008; doi:10.1038/leu.2008.166
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib
C Yang, P Lu, F Y Lee, A Chadburn, J C Barrientos, J P Leonard, F Ye, D Zhang, D M Knowles and Y L Wang
Leukemia 22: 1755-1766; advance online publication, July 3, 2008; doi:10.1038/leu.2008.163
Myeloma
Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma
C Jakob, J Sterz, P Liebisch, M Mieth, J Rademacher, A Goerke, U Heider, C Fleissner, M Kaiser, I von Metzler, C Müller and O Sezer
Leukemia 22: 1767-1772; advance online publication, June 26, 2008; doi:10.1038/leu.2008.159
Letters to the Editor
Identification of marker genes including RUNX3 (AML2) that discriminate between different myeloproliferative neoplasms and normal individuals
C I Müller, Q T Luong, L-Y Shih, L C Jones, J C Desmond, N Kawamata, O Tcherniantchouk, Q Liu, K Ito, M Osato, Y Ito, A Tefferi, S de Vos and H P Koeffler
Leukemia 22: 1773-1778; advance online publication, March 6, 2008; doi:10.1038/leu.2008.41
Association between high expression of natural killer related-genes (NCAM/CD94) and early death during induction in children with acute myeloid leukemia
L LoNigro, E Mirabile, S Munda, M Barchitta, D Bottino, A Fazzio, A Di Cataldo, A Agodi and G Schilirò
Leukemia 22: 1778-1781; advance online publication, March 6, 2008; doi:10.1038/leu.2008.46
Fludarabine combination therapy for follicular lymphoma followed by acute myeloid leukemia: two further case records
P Bernardeschi, G Fiorentini, P Dentico, S Rossi, G Turrisi, A Del Conte, P G Giannessi, G Giustarini and I Montenora
Leukemia 22: 1781-1782; advance online publication, March 13, 2008; doi:10.1038/leu.2008.51
Successful treatment of multicentric Castleman's disease with combined immunochemotherapy in an AIDS patient with multiorgan failure
S M Schmidt, A Raible, F Kortüm, F Mayer, R Riessen, P Adam, M Gregor and A L Bissinger
Leukemia 22: 1782-1785; advance online publication, May 1, 2008; doi:10.1038/leu.2008.54
Allogeneic transplantation of multiple umbilical cord blood units in adults: role of pretransplant-mixed lymphocyte reaction to predict host-vs-graft rejection
L R Fanning, Y Hegerfeldt, M Tary-Lehmann, M Lesniewski, J Maciejewski, R P Weitzel, M Kozik, M Finney, H M Lazarus, P Paul, M Z Ratajczak, H J Meyerson and M J Laughlin
Leukemia 22: 1786-1790; advance online publication, March 20, 2008; doi:10.1038/leu.2008.55
TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients
T L Lasho, A Tefferi, J D Hood, S Verstovsek, D G Gilliland and A Pardanani
Leukemia 22: 1790-1792; advance online publication, March 20, 2008; doi:10.1038/leu.2008.56
Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the 'second hit' hypothesis
H Becker, D Pfeifer, J D Afonso, S D Nimer, H Veelken, M Schwabe and M Lübbert
Leukemia 22: 1792-1794; advance online publication, April 3, 2008; doi:10.1038/leu.2008.61
BIC is processed efficiently to microRNA-155 in Burkitt lymphoma cells
T Zhang, K Nie and W Tam
Leukemia 22: 1795-1797; advance online publication, March 20, 2008; doi:10.1038/leu.2008.62
Transformation of severe congenital neutropenia to early acute lymphoblastic leukemia in a patient with HAX1 mutation and without G-CSF administration or receptor mutation
S Yetgin, L Olcay, A Koç and M Germeshausen
Leukemia 22: 1797; advance online publication, March 20, 2008; doi:10.1038/leu.2008.64
Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia
L Huang, W J E Tissing, R de Jonge, B D van Zelst and R Pieters
Leukemia 22: 1798-1800; advance online publication, March 27, 2008; doi:10.1038/leu.2008.66
Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis
S Quellmann, G Schwarzer, K Hübel, A Engert and J Bohlius
Leukemia 22: 1801-1803; advance online publication, May 1, 2008; doi:10.1038/leu.2008.105
Rac guanosine triphosphatases represent a potential target in AML
L U W Müller, R J Schore, Y Zheng, E K Thomas, M-O Kim, J A Cancelas, Y Gu and D A Williams
Leukemia 22: 1803-1806; advance online publication, July 31, 2008; doi:10.1038/leu.2008.196
Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis
J S Khorashad, V A De Melo, H Fiegler, G Gerrard, D Marin, J F Apperley, J M Goldman, L Foroni and A G Reid
Leukemia 22: 1806-1807; advance online publication, July 31, 2008; doi:10.1038/leu.2008.210
Inv(11)(q21q23) fuses MLL to the Notch co-activator mastermind-like 2 in secondary T-cell acute lymphoblastic leukemia
M Metzler, M S Staege, L Harder, D Mendelova, J Zuna, E Fronkova, C Meyer, T Flohr, D Bednarova, J Harbott, T Langer, S Gesk, J Trka, R Siebert, T Dingermann, R Marschalek, C Niemeyer and W Rascher
Leukemia 22: 1807-1811; advance online publication, March 13, 2008; doi:10.1038/leu.2008.50
Corrigenda
Inv(11)(q21q23) fuses MLL to the Notch co-activator mastermind-like 2 in secondary T-cell acute lymphoblastic leukemia FREE
M Metzler, M S Staege, L Harder, D Mendelova, J Zuna, E Fronkova, C Meyer, T Flohr, D Bednarova, J Harbott, T Langer, S Gesk, J Trka, R Siebert, T Dingermann, R Marschalek, C Niemeyer and W Rascher
Leukemia 22: 1812; doi:10.1038/leu.2008.104
Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma FREE
C Jakob, J Sterz, P Liebisch, M Mieth, J Rademacher, A Goerke, U Heider, C Fleissner, M Kaiser, I von Metzler, C Müller and O Sezer
Leukemia 22: 1812; doi:10.1038/leu.2008.201
